Kevin Bitterman, an insider at Disc Medicine Inc (IRON), sold 337,698 shares of the company on December 15, 2025, at a price of $91.24 per share, resulting in a total transaction value of $30.81 million. Following this sale, Bitterman retains 337,698 shares of the company.
Disc Medicine, based in Watertown, Massachusetts, is a clinical-stage biopharmaceutical firm focused on developing treatments for hematologic diseases. The company, which went public on August 12, 2020, has a market capitalization of $3.5 billion and reported a trailing twelve-month EPS of -5.35. Its pipeline includes several promising candidates, such as bitopertin for erythropoietic porphyrias and DISC-0974 for anemia associated with myelofibrosis and chronic kidney disease.
Insider transactions are reported to the SEC, offering transparency regarding how executives view their company's stock. While such sales can occur for various personal or financial reasons, they should not singularly dictate investment decisions. Investors are encouraged to analyze insider activity patterns over time and across multiple insiders to gain a clearer understanding of potential market signals.
Looking ahead, Disc Medicine is set to announce its next earnings report on August 5, 2026, with an estimated EPS of -1.64 and projected revenue of $5.7 million.